These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 8207366)

  • 1. Relationships between plasma levels of catecholamines and neuropeptides and the survival time in patients with congestive heart failure.
    Valdemarsson S; Bergdahl A; Edvinsson L
    J Intern Med; 1994 Jun; 235(6):595-601. PubMed ID: 8207366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased plasma level of substance P in patients with severe congestive heart failure treated with ACE inhibitors.
    Valdemarsson S; Edvinsson L; Ekman R; Hedner P; Sjöholm A
    J Intern Med; 1991 Oct; 230(4):325-31. PubMed ID: 1717629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of plasma catecholamines, plasma renin activity, and plasma atrial natriuretic peptide at rest and during exercise in congestive heart failure: comparison with clinical evaluation, ejection fraction, and exercise capacity.
    Madsen BK; Keller N; Christiansen E; Christensen NJ
    J Card Fail; 1995 Jun; 1(3):207-16. PubMed ID: 9420653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct comparison between endothelin-1, N-terminal proatrial natriuretic factor, and brain natriuretic peptide as prognostic markers of survival in congestive heart failure.
    Selvais PL; Robert A; Ahn S; van Linden F; Ketelslegers JM; Pouleur H; Rousseau MF
    J Card Fail; 2000 Sep; 6(3):201-7. PubMed ID: 10997745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of digoxin on atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP) and cyclic 3', 5'-guanosine monophosphate (cGMP) in patients with chronic congestive heart failure].
    Kobusiak-Prokopowicz M; Swidnicka-Szuszkowska B; Mysiak A
    Pol Arch Med Wewn; 2001 Jun; 105(6):475-82. PubMed ID: 11865578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Catecholamines, renin-angiotensin-aldosterone system, and atrial natriuretic peptide at rest and during submaximal exercise in patients with congestive heart failure.
    Kinugawa T; Ogino K; Kitamura H; Saitoh M; Omodani H; Osaki S; Hisatome I; Miyakoda H
    Am J Med Sci; 1996 Sep; 312(3):110-7. PubMed ID: 8783676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurohormonal activation in patients with mild or moderately severe congestive heart failure and effects of ramipril. The Ramipril Trial Study Group.
    Sigurdsson A; Amtorp O; Gundersen T; Nilsson B; Remes J; Swedberg K
    Br Heart J; 1994 Nov; 72(5):422-7. PubMed ID: 7818958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of angiotensin converting enzyme inhibition on relation of atrial natriuretic peptide concentration to atrial pressure in heart failure.
    Berglund H; Nyquist O; Beermann B; Jensen-Urstad M; Theodorsson E
    Br Heart J; 1994 Dec; 72(6):521-7. PubMed ID: 7857733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiac natriuretic peptides for diagnosis and risk stratification in heart failure: influences of left ventricular dysfunction and coronary artery disease on cardiac hormonal activation.
    Selvais PL; Donckier JE; Robert A; Laloux O; van Linden F; Ahn S; Ketelslegers JM; Rousseau MF
    Eur J Clin Invest; 1998 Aug; 28(8):636-42. PubMed ID: 9767358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gamma 2-MSH in congestive heart failure: relation to atrial natriuretic peptide, arginine vasopressin and catecholamines.
    Edvinsson L; Ekman R; Hedner P; Sjöholm A; Valdemarsson S
    J Intern Med; 1990 Mar; 227(3):183-7. PubMed ID: 2138208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.
    von Haehling S; Jankowska EA; Morgenthaler NG; Vassanelli C; Zanolla L; Rozentryt P; Filippatos GS; Doehner W; Koehler F; Papassotiriou J; Kremastinos DT; Banasiak W; Struck J; Ponikowski P; Bergmann A; Anker SD
    J Am Coll Cardiol; 2007 Nov; 50(20):1973-80. PubMed ID: 17996563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Congestive heart failure: involvement of perivascular peptides reflecting activity in sympathetic, parasympathetic and afferent fibres.
    Edvinsson L; Ekman R; Hedner P; Valdemarsson S
    Eur J Clin Invest; 1990 Feb; 20(1):85-9. PubMed ID: 2108040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Atrial natriuretic factor, catecholamines and the renin-angiotensin system in cardiac insufficiency. Relation to hemodynamic parameters].
    Komajda M; Carayon A; Nguyen JP; Maistre G; Drobinski G; Legrand S; Landault C; Legrand JC; Grosgogeat Y
    Arch Mal Coeur Vaiss; 1988 Jul; 81(7):845-53. PubMed ID: 2973293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between plasma levels of cardiac natriuretic peptides and soluble Fas: plasma soluble Fas as a prognostic predictor in patients with congestive heart failure.
    Tsutamoto T; Wada A; Maeda K; Mabuchi N; Hayashi M; Tsutsui T; Ohnishi M; Fujii M; Matsumoto T; Yamamoto T; Takayama T; Kinoshita M
    J Card Fail; 2001 Dec; 7(4):322-8. PubMed ID: 11782855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure.
    Berger R; Huelsman M; Strecker K; Bojic A; Moser P; Stanek B; Pacher R
    Circulation; 2002 May; 105(20):2392-7. PubMed ID: 12021226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Responses of plasma concentrations of A type natriuretic peptide and B type natriuretic peptide to alacepril, an angiotensin-converting enzyme inhibitor, in patients with congestive heart failure.
    Yoshimura M; Yasue H; Tanaka H; Kikuta K; Sumida H; Kato H; Jougasaki M; Nakao K
    Br Heart J; 1994 Dec; 72(6):528-33. PubMed ID: 7857734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adrenomedullin, endothelin, neuropeptide Y, atrial, brain, and C-natriuretic prohormone peptides compared as early heart failure indicators.
    Daggubati S; Parks JR; Overton RM; Cintron G; Schocken DD; Vesely DL
    Cardiovasc Res; 1997 Nov; 36(2):246-55. PubMed ID: 9463636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beta-blockers influence the short-term and long-term prognostic information of natriuretic peptides and catecholamines in chronic heart failure independent from specific agents.
    Frankenstein L; Nelles M; Slavutsky M; Schellberg D; Doesch A; Katus H; Remppis A; Zugck C
    J Heart Lung Transplant; 2007 Oct; 26(10):1033-9. PubMed ID: 17919624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How does treatment influence endocrine mechanisms in acute severe heart failure? Effects on cardiac natriuretic peptides, the renin system, neuropeptide Y and catecholamines.
    Missouris CG; Grouzmann E; Buckley MG; Barron J; MacGregor GA; Singer DR
    Clin Sci (Lond); 1998 Jun; 94(6):591-9. PubMed ID: 9854456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Level and diurnal variations of hormones of interest to the cardiovascular system in patients with heart transplants.
    Sehested J; Thomas F; Thorn M; Schifter S; Regitz V; Sheikh S; Oelkers W; Palm U; Meyer-Sabellek W; Hetzer R
    Am J Cardiol; 1992 Feb; 69(4):397-402. PubMed ID: 1531162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.